\-\ Texto\\:\\ \ \(0\)\
\-\ bilateral\\ mastectomy\\ was\\ advised\\.\ \(0\)\
\-\ bilateral\\ circumscribed\\ masses\\,\\ the\\ mass\\ on\\ left\\ is\\ associated\\ with\\ pleomorphic\\ calcifications\\.\ \(0\)\
\-\ bilateral\\ breast\\ carcinoma\ \(0\)\
\-\ fibroadenoma\ \(22\)\
\-\ cysts\ \(539\)\
\-\ malignancy\\ \\(primary\\ or\\ metastatic\\)\ \(1\)\
\-\ asymptomatic\\.\ \(81\)\
\-\ pathologic\\ diagnosis\\ on\\ both\\ left\\ and\\ right\\ side\\:\\ papillary\\ carcinoma\\ in\\ situ\\,lobular\\ carcinoma\\ and\\ ductal\\ carcinoma\\ in\\ situ\\.\\ \\ \ \(0\)\
\-\ the\\ patient\\ in\\ the\\ above\\ case\\ has\\ elected\\ to\\ have\\ breast\\ conserving\\ therapy\\,\\ despite\\ recommendation\\ for\\ bilateral\\ mastectomy\\.\\ \ \(0\)\
\-\ in\\ a\\ recent\\ study\\ based\\ in\\ the\\ netherlands\\*\\,\\ patients\\ with\\ synchronous\\ breast\\ cancer\\ \\(defined\\ as\\ bilateral\\ breast\\ cancer\\ \\â\\€\\“\\ bbc\\ \\-\\ cancer\\ diagnosed\\ in\\ both\\ breasts\\ at\\ the\\ same\\ time\\ or\\ within\\ a\\ period\\ of\\ 3\\ months\\ of\\ diagnosis\\ of\\ the\\ first\\ tumor\\)\\ had\\ a\\ worse\\ prognosis\\ and\\ survival\\ than\\ in\\ patients\\ with\\ unilateral\\ breast\\ cancer\\ \\(ubc\\)\\.\\ \\ \\ patients\\ with\\ bbc\\ showed\\ a\\ higher\\ proportion\\ of\\ tubular\\ carcinoma\\ and\\ medially\\ located\\ tumors\\,\\ a\\ greater\\ 5\\-\\ and\\ 10\\-year\\ local\\ recurrence\\ rate\\ and\\ nearly\\ double\\ the\\ 5\\-\\ and\\ 10\\-year\\ distant\\ metastasis\\ rate\\.\ \(0\)\
\-\ as\\ synchronous\\ breast\\ carcinoma\\ represents\\ a\\ minority\\ of\\ cases\\ \\(1\\.5\\%\\)\\,\\ it\\â\\€\\™s\\ optimal\\ management\\ continues\\ to\\ be\\ under\\ debate\\.\ \(0\)\
\-\ \\*synchronous\\,\\ bilateral\\ breast\\ cancer\\:\\ prognostic\\ value\\ and\\ incidence\\,\\ \\ the\\ breast\\,\\ volume\\ 12\\,\\ issue\\ 2\\ \\,\\ april\\ 2003\\,\\ pages\\ 83\\-88\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.11309624910602878\ \(0\)\
\-\ synchronous\\:\\ 0\\.0999447183342593\ \(0\)\
\-\ bbc\\:\\ 0\\.079062945506426\ \(0\)\
\-\ 5\\-\\:\\ 0\\.07284637886463276\ \(0\)\
\-\ 10\\-year\\:\\ 0\\.07284637886463276\ \(0\)\
\-\ carcinoma\\:\\ 0\\.06516397318428341\ \(0\)\
\-\ cancer\\:\\ 0\\.06298576825929966\ \(0\)\
\-\ bilateral\\:\\ 0\\.05579778643895365\ \(0\)\
\-\ situ\\:\\ 0\\.049842348752870094\ \(0\)\
\-\ mastectomy\\:\\ 0\\.045541244894019096\ \(0\)\
\-\ \\*\\:\\ 0\\.04264641626385721\ \(0\)\
\-\ \\-cysts\\:\\ 0\\.039531472753213\ \(0\)\
\-\ 83\\-88\\:\\ 0\\.039531472753213\ \(0\)\
\-\ netherlands\\:\\ 0\\.03642318943231638\ \(0\)\
\-\ conserving\\:\\ 0\\.03460496024797483\ \(0\)\
\-\ \\-fibroadenoma\\:\\ 0\\.03331490611141977\ \(0\)\
\-\ ubc\\:\\ 0\\.03331490611141977\ \(0\)\
\-\ minority\\:\\ 0\\.03231426238355335\ \(0\)\
\-\ \\-malignancy\\:\\ 0\\.030805418273144328\ \(0\)\
\-\ pages\\:\\ 0\\.03020662279052315\ \(0\)\
\-\ rate\\:\\ 0\\.029871941618617427\ \(0\)\
\-\ patients\\:\\ 0\\.029752124655148333\ \(0\)\
\-\ debate\\:\\ 0\\.029678447742736674\ \(0\)\
\-\ proportion\\:\\ 0\\.029205979062656737\ \(0\)\
\-\ optimal\\:\\ 0\\.02769713495224771\ \(0\)\
\-\ elected\\:\\ 0\\.02738774987831519\ \(0\)\
\-\ april\\:\\ 0\\.02738774987831519\ \(0\)\
\-\ recommendation\\:\\ 0\\.026826480178969873\ \(0\)\
\-\ issue\\:\\ 0\\.026570164421840063\ \(0\)\
\-\ prognostic\\:\\ 0\\.02567029583232369\ \(0\)\
\-\ advised\\:\\ 0\\.024132426993189918\ \(0\)\
\-\ breasts\\:\\ 0\\.02371819685807326\ \(0\)\
\-\ distant\\:\\ 0\\.0223626772532619\ \(0\)\
\-\ medially\\:\\ 0\\.021812891055538432\ \(0\)\
\-\ value\\:\\ 0\\.021727473140871645\ \(0\)\
\-\ lobular\\:\\ 0\\.0216436519166019\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.021561368783560658\ \(0\)\
\-\ nearly\\:\\ 0\\.021097060806247476\ \(0\)\
\-\ survival\\:\\ 0\\.020544448068920352\ \(0\)\
\-\ continues\\:\\ 0\\.01999466187119689\ \(0\)\
\-\ both\\:\\ 0\\.01957130036489795\ \(0\)\
\-\ papillary\\:\\ 0\\.019453729190530455\ \(0\)\
\-\ 2003\\:\\ 0\\.01925439393236528\ \(0\)\
\-\ 1\\.5\\:\\ 0\\.019157953550208495\ \(0\)\
\-\ unilateral\\:\\ 0\\.01901707374647137\ \(0\)\
\-\ higher\\:\\ 0\\.018791684352835097\ \(0\)\
\-\ double\\:\\ 0\\.018535368595705284\ \(0\)\
\-\ represents\\:\\ 0\\.018412503240601633\ \(0\)\
\-\ prognosis\\:\\ 0\\.018176432686855346\ \(0\)\
\-\ volume\\:\\ 0\\.018100425698901204\ \(0\)\
\-\ ductal\\:\\ 0\\.018062899915625347\ \(0\)\
\-\ period\\:\\ 0\\.017915860351396688\ \(0\)\
\-\ tubular\\:\\ 0\\.01784410994177139\ \(0\)\
\-\ despite\\:\\ 0\\.017808660706313484\ \(0\)\
\-\ local\\:\\ 0\\.017601656034729796\ \(0\)\
\-\ diagnosis\\:\\ 0\\.017598379648254888\ \(0\)\
\-\ incidence\\:\\ 0\\.017568065578545233\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.017245314459150212\ \(0\)\
\-\ circumscribed\\:\\ 0\\.017032460032069836\ \(0\)\
\-\ worse\\:\\ 0\\.016973455168493554\ \(0\)\
\-\ pathologic\\:\\ 0\\.016772845779070275\ \(0\)\
\-\ under\\:\\ 0\\.016744906094089844\ \(0\)\
\-\ recurrence\\:\\ 0\\.01671713941136374\ \(0\)\
\-\ defined\\:\\ 0\\.016146110611468666\ \(0\)\
\-\ same\\:\\ 0\\.015794679817228728\ \(0\)\
\-\ located\\:\\ 0\\.015772202051203863\ \(0\)\
\-\ 12\\:\\ 0\\.015683401031938483\ \(0\)\
\-\ based\\:\\ 0\\.014612961265771123\ \(0\)\
\-\ \\,\\:\\ 0\\.014567357785683627\ \(0\)\
\-\ management\\:\\ 0\\.014459782257648615\ \(0\)\
\-\ tumors\\:\\ 0\\.014393346895383413\ \(0\)\
\-\ greater\\:\\ 0\\.014393346895383413\ \(0\)\
\-\ metastasis\\:\\ 0\\.014344158413901017\ \(0\)\
\-\ calcifications\\:\\ 0\\.014247371097007858\ \(0\)\
\-\ diagnosed\\:\\ 0\\.014090561241233208\ \(0\)\
\-\ above\\:\\ 0\\.01404456796694088\ \(0\)\
\-\ side\\:\\ 0\\.013275544850959959\ \(0\)\
\-\ in\\:\\ 0\\.013227715744312935\ \(0\)\
\-\ \\(\\:\\ 0\\.012957161008858485\ \(0\)\
\-\ masses\\:\\ 0\\.012953329138995906\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.012953329138995906\ \(0\)\
\-\ recent\\:\\ 0\\.012882148201075323\ \(0\)\
\-\ first\\:\\ 0\\.01285867011114732\ \(0\)\
\-\ \\)\\:\\ 0\\.012798882369745383\ \(0\)\
\-\ cases\\:\\ 0\\.012765967999915391\ \(0\)\
\-\ study\\:\\ 0\\.012608212362600714\ \(0\)\
\-\ showed\\:\\ 0\\.012564140214904469\ \(0\)\
\-\ as\\:\\ 0\\.011592623371247782\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.011453034706930295\ \(0\)\
\-\ primary\\:\\ 0\\.011351498936752002\ \(0\)\
\-\ s\\:\\ 0\\.010989989538630436\ \(0\)\
\-\ time\\:\\ 0\\.010823323888965527\ \(0\)\
\-\ a\\:\\ 0\\.010670846685702277\ \(0\)\
\-\ months\\:\\ 0\\.010466104460493576\ \(0\)\
\-\ therapy\\:\\ 0\\.010245025992110373\ \(0\)\
\-\ \\:\\:\\ 0\\.01013699386538713\ \(0\)\
\-\ than\\:\\ 0\\.010040577824745623\ \(0\)\
\-\ metastatic\\:\\ 0\\.009646230509489194\ \(0\)\
\-\ associated\\:\\ 0\\.009042433013039022\ \(0\)\
\-\ or\\:\\ 0\\.008982266806849395\ \(0\)\
\-\ 3\\:\\ 0\\.008972984424693003\ \(0\)\
\-\ \\%\\:\\ 0\\.008938659342358778\ \(0\)\
\-\ tumor\\:\\ 0\\.008933777137268211\ \(0\)\
\-\ it\\:\\ 0\\.008613669885798281\ \(0\)\
\-\ left\\:\\ 0\\.008574935150429728\ \(0\)\
\-\ case\\:\\ 0\\.008383427950077448\ \(0\)\
\-\ have\\:\\ 0\\.008297928602534043\ \(0\)\
\-\ had\\:\\ 0\\.008268384839644432\ \(0\)\
\-\ 2\\:\\ 0\\.008251589670450879\ \(0\)\
\-\ \\-\\:\\ 0\\.008214028962817773\ \(0\)\
\-\ within\\:\\ 0\\.007310006315632653\ \(0\)\
\-\ has\\:\\ 0\\.007195963993247883\ \(0\)\
\-\ on\\:\\ 0\\.006492296075026261\ \(0\)\
\-\ and\\:\\ 0\\.006457722178734294\ \(0\)\
\-\ be\\:\\ 0\\.005909222974636454\ \(0\)\
\-\ mass\\:\\ 0\\.005329421555818675\ \(0\)\
\-\ at\\:\\ 0\\.005191763017182211\ \(0\)\
\-\ the\\:\\ 0\\.004959615594748908\ \(0\)\
\-\ was\\:\\ 0\\.00443173776777438\ \(0\)\
\-\ right\\:\\ 0\\.004043191520674515\ \(0\)\
\-\ patient\\:\\ 0\\.0038412194211497218\ \(0\)\
\-\ to\\:\\ 0\\.003830207250609742\ \(0\)\
\-\ for\\:\\ 0\\.0032695432674561217\ \(0\)\
\-\ of\\:\\ 0\\.0026121928430042247\ \(0\)\
\-\ is\\:\\ 0\\.0025214833111422675\ \(0\)\
\-\ with\\:\\ 0\\.0020987296159621477\ \(0\)\
\-\ \\.\\:\\ 0\\.0012735259586491936\ \(0\)\
